TOPICAL 0.09% BROMFENAC SODIUM FOR INTRAOPERATIVE MIOSIS AND PAIN REDUCTION IN FEMTOSECOND LASER-ASSISTED CATARACT SURGERY v1

Abstract Purpose:To evaluate the effect of bromfenac ophthalmic solution 0.09% for reduction of intraoperative miosis and pain in patient who have undergone femtosecond laser-assisted cataract surgery. Methods: This prospective cross-sectional randomized clinical study included 60 patients with senile cataract in the absence of significant ocular comorbidity. The patients received 0.09% bromfenac ophthalmic solution or control placebo twice a day for 3 days before surgery. Pupil diameter was measured at the initiation and finalization of femtosecond laser-assisted cataract surgery and pain quantification was assessed by analogous pain scale at one day follow-up. Results:Baseline characteristics were comparable between groups for age and gender. Compared with patients who were not treated, there was a significant difference in maintaining pupil dilation throughout the operation when the patients were treated with 0.09% bromfenac (p<0.001). Compared with untreated patients, quantification of pain at one day follow-up of procedure was lower in the 0.09% bromfenac group (p<0.001). 15 patients in the group receiving presurgical NSAIDs had a pain score of 1 versus 1 patient who received only placebo. Conclusion: The maintenance of pupil dilation and the prevention of miosis were more effective in the 0,09% Bromfenac group than in the control group. Likewise, greater control of postoperative pain represented an additional significant benefit.